Page 1055 - Clinical Immunology_ Principles and Practice ( PDFDrive )

1018 Part seven Organ-Specific Inflammatory Disease

34. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe 57. Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis
Crohn’s disease: a phase 2, randomized, double-blind, placebo-controlled, - proposal for a scoring system and review of the literature. Aliment
multiple-dose study. Inflamm Bowel Dis 2010;16:233–42. Pharmacol Ther 2005;22:277–84.
35. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for 58. Pardi DS, Kelly CP. Microscopic colitis. Gastroenterology
active Crohn’s disease. N Engl J Med 2004;351:2069–79. 2011;140:1155–65.
36. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and 59. Stewart MJ, Seow CH, Storr MA. Prednisolone and budesonide for
maintenance therapy in refractory Crohn’s disease. N Engl J Med short- and long-term treatment of microscopic colitis: systematic review
2012;367:1519–28. and meta-analysis. Clin Gastroenterol Hepatol 2011;9:881–90.
37. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL- 60. Esteve M, Mahadevan U, Sainz E, et al. Efficacy of anti-TNF therapies in
17A monoclonal antibody, for moderate to severe Crohn’s disease: refractory severe microscopic colitis. J Crohns Colitis 2011;5:612–18.
unexpected results of a randomised, double-blind placebo-controlled 61. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in
trial. Gut 2012;61:1693–700. children and adults: a systematic review and consensus recommendations
38. McGovern DP, Kugathasan S, Cho JH. Genetics of Inflammatory Bowel for diagnosis and treatment. Gastroenterology 2007;133:1342–63.
Diseases. Gastroenterology 2015;149:1163–76, e2. 62. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J
39. Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an Med 2004;351:940–1.
intracellular pathogen induced by a Crohn’s disease associated ATG16L1 63. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression
variant. PLoS ONE 2008;3:e3391. by oesophageal squamous cells from patients with eosinophilic
40. Murthy A, Li Y, Peng I, et al. A Crohn’s disease variant in Atg16l1 oesophagitis and GORD. Gut 2013;62:824–32.
enhances its degradation by caspase 3. Nature 2014;506:456–62. 64. Nurko S, Rosen R. Esophageal dysmotility in patients who have
41. Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 eosinophilic esophagitis. Gastrointest Endosc Clin N Am 2008;18:73–89,
receptor polymorphism results in decreased primary CD4+ and CD8+ ix.
human T-cell functional responses. Proc Natl Acad Sci USA 65. Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic
2011;108:9560–5. esophagitis provides insight into disease pathogenesis and treatment
42. Erickson AR, Cantarel BL, Lamendella R, et al. Integrated metagenomics/ strategies. J Allergy Clin Immunol 2011;128:23–32, quiz 33–4.
metaproteomics reveals human host-microbiota signatures of Crohn’s 66. Travers J, Rothenberg ME. Eosinophils in mucosal immune responses.
disease. PLoS ONE 2012;7:e49138. Mucosal Immunol 2015;8:464–75.
43. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of 67. Mehta P, Furuta GT. Eosinophils in Gastrointestinal Disorders:
anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil Eosinophilic Gastrointestinal Diseases, Celiac Disease, Inflammatory
cytoplasmic antibodies in inflammatory bowel disease. Am J Bowel Diseases, and Parasitic Infections. Immunol Allergy Clin North Am
Gastroenterol 2006;101:2410–22. 2015;35:413–37.
44. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects 68. Uhlig HH. Monogenic diseases associated with intestinal inflammation:
and established and evolving therapies. Lancet 2007;369:1641–57. implications for the understanding of inflammatory bowel disease. Gut
45. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or 2013;62:1795–805.
combination therapy for Crohn’s disease. N Engl J Med 69. Malamut G, Verkarre V, Suarez F, et al. The enteropathy associated with
2010;362:1383–95. common variable immunodeficiency: the delineated frontiers with celiac
46. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and disease. Am J Gastroenterol 2010;105:2262–75.
inflammatory bowel disease: epidemiology, risk factors, mechanisms of 70. Mannon PJ, Fuss IJ, Dill S, et al. Excess IL-12 but not IL-23 accompanies
carcinogenesis and prevention strategies. Anticancer Res 2009;29:2727–37. the inflammatory bowel disease associated with common variable
47. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and immunodeficiency. Gastroenterology 2006;131:748–56.
progression of ulcerative colitis. A long-term follow-up of 1116 patients. 71. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders
Dig Dis Sci 1993;38:1137–46. in patients with primary immunodeficiency. Clin Gastroenterol Hepatol
48. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of 2013;11:1050–63.
inflammatory bowel disease associated with primary sclerosing 72. Washington K, Stenzel TT, Buckley RH, et al. Gastrointestinal pathology
cholangitis. Gut 2005;54:91–6. in patients with common variable immunodeficiency and X-linked
49. Fuss IJ, Strober W. The role of IL-13 and NK T cells in experimental and agammaglobulinemia. Am J Surg Pathol 1996;20:1240–52.
human ulcerative colitis. Mucosal Immunol 2008;1:S31–3. 73. Sanges M, Spadaro G, Miniero M, et al. Efficacy of subcutaneous
50. Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis immunoglobulins in primary immunodeficiency with Crohn’s-like
model resembling ulcerative colitis, is mediated by IL-13-producing phenotype: report of a case. Eur Rev Med Pharmacol Sci 2015;19:2641–5.
NK-T cells. Immunity 2002;17:629–38. 74. Akazawa Y, Takeshima F, Yajima H, et al. Infliximab therapy for
51. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T Crohn’s-like disease in common variable immunodeficiency complicated
cells that produce IL-13 characterize an atypical Th2 response in by massive intestinal hemorrhage: a case report. BMC Res Notes
ulcerative colitis. J Clin Invest 2004;113:1490–7. 2014;7:382.
52. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 75. Matute JD, Arias AA, Wright NA, et al. A new genetic subgroup of
cytokine in ulcerative colitis that affects epithelial tight junctions, chronic granulomatous disease with autosomal recessive mutations in
apoptosis, and cell restitution. Gastroenterology 2005;129:550–64. p40 phox and selective defects in neutrophil NADPH oxidase activity.
53. Reinisch W, Panes J, Khurana S, et al. Anrukinzumab, an anti-interleukin Blood 2009;114:3309–15.
13 monoclonal antibody, in active UC: efficacy and safety from a phase 76. Barton LL, Moussa SL, Villar RG, et al. Gastrointestinal complications of
IIa randomised multicentre study. Gut 2015;64:894–900. chronic granulomatous disease: case report and literature review. Clin
54. Mokry M, Middendorp S, Wiegerinck CL, et al. Many inflammatory Pediatr (Phila) 1998;37:231–6.
bowel disease risk loci include regions that regulate gene expression in 77. Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal
immune cells and the intestinal epithelium. Gastroenterology involvement in chronic granulomatous disease. Pediatrics 2004;114:
2014;146:1040–7. 462–8.
55. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: 78. Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for
American College Of Gastroenterology, Practice Parameters Committee. liver abscess in chronic granulomatous disease. Clin Infect Dis
Am J Gastroenterol 2010;105:501–23, quiz 524. 2012;54:694–700.
56. Kao KT, Pedraza BA, McClune AC, et al. Microscopic colitis: a large 79. Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma
retrospective analysis from a health maintenance organization experience. therapy for patients with chronic granulomatous disease. Clin Infect Dis
World J Gastroenterol 2009;15:3122–7. 2004;39:692–9.